B-intervention	0	11	Neoadjuvant
I-intervention	12	23	doxorubicin
I-intervention	23	24	/
I-intervention	24	40	cyclophosphamide
I-intervention	41	49	followed
I-intervention	50	52	by
I-intervention	53	64	ixabepilone
O	65	67	or
B-control	68	78	paclitaxel
O	79	81	in
O	82	87	early
O	88	93	stage
O	94	100	breast
O	101	107	cancer
O	108	111	and
O	112	122	evaluation
O	123	125	of
O	126	127	β
O	127	130	III
O	130	131	-
O	131	138	tubulin
O	139	149	expression
O	150	152	as
O	153	154	a
O	155	165	predictive
O	166	172	marker
O	172	173	.

O	174	178	This
O	179	189	randomized
O	190	195	phase
O	196	198	II
O	199	204	trial
O	205	208	was
O	209	217	designed
O	218	220	to
O	221	228	compare
O	229	232	the
O	233	237	rate
O	238	240	of
O	241	251	pathologic
O	252	260	complete
O	261	269	response
O	270	271	(
O	271	274	pCR
O	274	275	)
O	276	283	induced
O	284	286	by
O	287	298	neoadjuvant
O	299	315	cyclophosphamide
O	316	320	plus
O	321	332	doxorubicin
O	333	334	(
O	334	336	AC
O	336	337	)
O	338	346	followed
O	347	349	by
O	350	361	ixabepilone
O	362	364	or
O	365	375	paclitaxel
O	376	378	in
O	379	384	women
O	385	389	with
O	390	395	early
O	396	401	stage
O	402	408	breast
O	409	415	cancer
O	416	417	(
O	417	419	BC
O	419	420	)
O	420	421	.

O	422	432	Expression
O	433	435	of
O	436	437	β
O	437	440	III
O	440	441	-
O	441	448	tubulin
O	449	451	as
O	452	453	a
O	454	464	predictive
O	465	471	marker
O	472	475	was
O	476	480	also
O	481	490	evaluated
O	490	491	.

B-eligibility	492	497	Women
I-eligibility	498	502	with
I-eligibility	503	512	untreated
I-eligibility	512	513	,
I-eligibility	514	528	histologically
I-eligibility	529	538	confirmed
I-eligibility	539	546	primary
I-eligibility	547	555	invasive
I-eligibility	556	562	breast
I-eligibility	563	577	adenocarcinoma
O	578	586	received
O	587	591	four
O	592	598	cycles
O	599	601	of
O	602	604	AC
O	605	613	followed
O	614	616	by
O	617	618	1
O	618	619	:
O	619	620	1
O	621	634	randomization
O	635	637	to
O	638	644	either
O	645	656	ixabepilone
O	657	659	40
O	660	662	mg
O	662	663	/
O	663	665	m2
O	666	667	(
O	667	668	3
O	668	669	-
O	669	673	hour
O	674	682	infusion
O	682	683	)
O	684	689	every
O	690	691	3
O	692	697	weeks
O	698	701	for
O	702	706	four
O	707	713	cycles
O	714	715	(
O	715	716	n
O	717	718	=
B-intervention-participants	719	722	148
O	722	723	)
O	724	726	or
O	727	733	weekly
O	734	744	paclitaxel
O	745	747	80
O	748	750	mg
O	750	751	/
O	751	753	m2
O	754	755	(
O	755	756	1
O	756	757	-
O	757	761	hour
O	762	770	infusion
O	770	771	)
O	772	775	for
O	776	778	12
O	779	784	weeks
O	785	786	(
O	786	787	n
O	788	789	=
B-control-participants	790	793	147
O	793	794	)
O	794	795	.

O	796	799	All
O	800	808	patients
O	809	818	underwent
O	819	820	a
O	821	825	core
O	826	832	needle
O	833	839	biopsy
O	840	842	of
O	843	846	the
O	847	854	primary
O	855	861	cancer
O	862	865	for
O	866	875	molecular
O	876	882	marker
O	883	891	analysis
O	892	897	prior
O	898	900	to
O	901	913	chemotherapy
O	913	914	.

O	915	916	β
O	916	919	III
O	919	920	-
O	920	927	Tubulin
O	928	938	expression
O	939	942	was
O	943	951	assessed
O	952	957	using
O	958	978	immunohistochemistry
O	978	979	.

O	980	985	There
O	986	989	was
O	990	992	no
O	993	1004	significant
O	1005	1015	difference
O	1016	1018	in
O	1019	1022	the
B-outcome	1023	1027	rate
I-outcome	1028	1030	of
I-outcome	1031	1034	pCR
O	1035	1037	in
O	1038	1041	the
O	1042	1053	ixabepilone
O	1054	1063	treatment
O	1064	1067	arm
O	1068	1069	(
B-iv-bin-percent	1069	1071	24
I-iv-bin-percent	1071	1072	.
I-iv-bin-percent	1072	1073	3
I-iv-bin-percent	1073	1074	%
O	1074	1075	;
O	1076	1078	90
O	1078	1079	%
O	1080	1090	confidence
O	1091	1099	interval
O	1100	1101	[
O	1101	1103	CI
O	1103	1104	]
O	1104	1105	,
O	1106	1108	18
O	1108	1109	.
O	1109	1110	6
O	1110	1111	-
O	1111	1113	30
O	1113	1114	.
O	1114	1115	8
O	1115	1116	)
O	1117	1120	and
O	1121	1124	the
O	1125	1135	paclitaxel
O	1136	1145	treatment
O	1146	1149	arm
O	1150	1151	(
B-cv-bin-percent	1151	1153	25
I-cv-bin-percent	1153	1154	.
I-cv-bin-percent	1154	1155	2
I-cv-bin-percent	1155	1156	%
O	1156	1157	;
O	1158	1160	90
O	1160	1161	%
O	1162	1164	CI
O	1164	1165	,
O	1166	1168	19
O	1168	1169	.
O	1169	1170	4
O	1170	1171	-
O	1171	1173	31
O	1173	1174	.
O	1174	1175	7
O	1175	1176	)
O	1176	1177	.

O	1178	1179	β
O	1179	1182	III
O	1182	1183	-
O	1183	1190	Tubulin
O	1190	1191	-
O	1191	1199	positive
O	1200	1208	patients
O	1209	1217	obtained
O	1218	1224	higher
O	1225	1228	pCR
O	1229	1234	rates
O	1235	1243	compared
O	1244	1248	with
O	1249	1250	β
O	1250	1253	III
O	1253	1254	-
O	1254	1261	tubulin
O	1261	1262	-
O	1262	1270	negative
O	1271	1279	patients
O	1280	1282	in
O	1283	1287	both
O	1288	1297	treatment
O	1298	1302	arms
O	1302	1303	;
O	1304	1311	however
O	1311	1312	,
O	1313	1314	β
O	1314	1317	III
O	1317	1318	-
O	1318	1325	tubulin
O	1326	1336	expression
O	1337	1340	was
O	1341	1344	not
O	1345	1358	significantly
O	1359	1369	associated
O	1370	1374	with
O	1375	1376	a
O	1377	1389	differential
O	1390	1398	response
O	1399	1401	to
O	1402	1413	ixabepilone
O	1414	1416	or
O	1417	1427	paclitaxel
O	1427	1428	.

O	1429	1432	The
O	1433	1439	safety
O	1440	1448	profiles
O	1449	1451	of
O	1452	1456	both
O	1457	1465	regimens
O	1466	1470	were
O	1471	1480	generally
O	1481	1488	similar
O	1488	1489	,
O	1490	1498	although
B-outcome	1499	1510	neutropenia
O	1511	1519	occurred
O	1520	1524	more
O	1525	1535	frequently
O	1536	1538	in
O	1539	1542	the
O	1543	1554	ixabepilone
O	1555	1558	arm
O	1559	1560	(
B-outcome	1560	1565	grade
I-outcome	1566	1567	3
I-outcome	1567	1568	/
I-outcome	1568	1569	4
O	1569	1570	:
B-iv-bin-percent	1571	1573	41
I-iv-bin-percent	1573	1574	.
I-iv-bin-percent	1574	1575	3
I-iv-bin-percent	1575	1576	%
O	1577	1579	vs
O	1579	1580	.
B-cv-bin-percent	1581	1582	8
I-cv-bin-percent	1582	1583	.
I-cv-bin-percent	1583	1584	4
I-cv-bin-percent	1584	1585	%
O	1585	1586	)
O	1586	1587	.

O	1588	1591	The
O	1592	1596	most
O	1597	1603	common
O	1604	1618	nonhematologic
O	1619	1627	toxicity
O	1628	1631	was
B-outcome	1632	1642	peripheral
I-outcome	1643	1653	neuropathy
O	1653	1654	.

O	1655	1666	Neoadjuvant
O	1667	1676	treatment
O	1677	1679	of
O	1680	1685	early
O	1686	1691	stage
O	1692	1694	BC
O	1695	1699	with
O	1700	1702	AC
O	1703	1711	followed
O	1712	1714	by
O	1715	1726	ixabepilone
O	1727	1732	every
O	1733	1734	3
O	1735	1740	weeks
O	1741	1743	or
O	1744	1750	weekly
O	1751	1761	paclitaxel
O	1762	1765	was
O	1766	1770	well
O	1771	1780	tolerated
O	1781	1785	with
O	1786	1788	no
O	1789	1800	significant
O	1801	1811	difference
O	1812	1814	in
O	1815	1823	efficacy
O	1823	1824	.

O	1825	1831	Higher
O	1832	1840	response
O	1841	1846	rates
O	1847	1851	were
O	1852	1860	observed
O	1861	1866	among
O	1867	1868	β
O	1868	1871	III
O	1871	1872	-
O	1872	1879	tubulin
O	1879	1880	-
O	1880	1888	positive
O	1889	1897	patients
O	1897	1898	.
